Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Resmed Inc (RMD)

Resmed Inc (RMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,522,512
  • Shares Outstanding, K 144,908
  • Annual Sales, $ 2,957 M
  • Annual Income, $ 621,670 K
  • 60-Month Beta 0.38
  • Price/Sales 8.96
  • Price/Cash Flow 30.26
  • Price/Book 10.59
Trade RMD with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.93
  • Number of Estimates 5
  • High Estimate 1.06
  • Low Estimate 0.72
  • Prior Year 0.93
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
165.92 +8.81%
on 10/02/20
183.70 -1.73%
on 10/23/20
+11.49 (+6.80%)
since 09/25/20
3-Month
165.72 +8.94%
on 09/21/20
207.04 -12.80%
on 07/27/20
-21.91 (-10.82%)
since 07/24/20
52-Week
108.85 +65.85%
on 03/23/20
208.99 -13.62%
on 07/23/20
+36.27 (+25.14%)
since 10/25/19

Most Recent Stories

More News
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

RMD : 180.53 (-1.37%)
NextGen Healthcare (NXGN) Gains 8.1% Post Q2 Earnings Beat

NextGen (NXGN) benefited from both its operating segments in Q2.

RMD : 180.53 (-1.37%)
IDXX : 428.96 (-0.16%)
PODD : 253.53 (+1.66%)
NXGN : 14.26 (-5.00%)
Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid

In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.

RMD : 180.53 (-1.37%)
ABT : 109.00 (+1.12%)
IDXX : 428.96 (-0.16%)
PODD : 253.53 (+1.66%)
Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales

Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.

RMD : 180.53 (-1.37%)
TMO : 482.43 (+0.47%)
IDXX : 428.96 (-0.16%)
PODD : 253.53 (+1.66%)
The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed

The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed

EW : 78.08 (-2.90%)
RMD : 180.53 (-1.37%)
QGEN : 49.26 (-1.10%)
LHCG : 220.60 (+1.70%)
IDXX : 428.96 (-0.16%)
3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings

Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.

EW : 78.08 (-2.90%)
RMD : 180.53 (-1.37%)
QGEN : 49.26 (-1.10%)
LHCG : 220.60 (+1.70%)
IDXX : 428.96 (-0.16%)
Intuitive Surgical (ISRG) Q3 Earnings Top Estimates, Down Y/Y

Intuitive Surgical's (ISRG) third-quarter results reflect improvement in procedure volume.

ISRG : 711.77 (-3.22%)
RMD : 180.53 (-1.37%)
ABT : 109.00 (+1.12%)
IDXX : 428.96 (-0.16%)
Zacks.com featured highlights include: Lowe's, ResMed, Artisan Partners and Northern Trust

Zacks.com featured highlights include: Lowe's, ResMed, Artisan Partners and Northern Trust

NTRS : 82.23 (-2.58%)
LOW : 168.13 (-2.33%)
RMD : 180.53 (-1.37%)
APAM : 42.67 (-1.34%)
Is ResMed (RMD) Outperforming Other Medical Stocks This Year?

Is (RMD) Outperforming Other Medical Stocks This Year?

RMD : 180.53 (-1.37%)
Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Down

Walgreens Boots' (WBA) fiscal fourth-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.

RMD : 180.53 (-1.37%)
ABT : 109.00 (+1.12%)
IDXX : 428.96 (-0.16%)
WBA : 37.21 (-2.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

ResMed Inc. is a world-leading connected health company with cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions....

See More

Key Turning Points

2nd Resistance Point 183.56
1st Resistance Point 182.05
Last Price 180.53
1st Support Level 179.13
2nd Support Level 177.73

See More

52-Week High 208.99
Last Price 180.53
Fibonacci 61.8% 170.74
Fibonacci 50% 158.92
Fibonacci 38.2% 147.11
52-Week Low 108.85

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar